Melosky B, et al. - Researchers assessed the efficacy and toxicity of selumetinib (AZD6244, ARRY142886), a MEK1/2 inhibitor combined with chemotherapy in patients with non-small cell lung cancer (NSCLC) in two schedules. Patients were administered pemetrexed/platinum chemotherapy in first line with two schedules of selumetinib (Arm A: intermittent given on days 2-19; Arm B: continuous given on days 1-21) vs chemotherapy alone (Arm C) in a three-arm study (IND.219). A higher response rate was observed in relation to selumetinib combined with chemotherapy. Compared to an intermittent schedule, the superiority of continuous selumetinib was suggested. Albeit not statistically significant, progression-free survival prolongation was achieved with the addition of selumetinib.